Engels

Sample ID, body site where sample was collected, analyte type of samples, tumor status, and histological type of samples obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.

6 Formulieren  
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, and subject source ID of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    3. Subject ID, family ID, father and mother IDs, and sex of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    4. Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    5. Subject ID, age, height, weight, tumor grade, tumor stage, histology of tumor, tumor ER, HER2, and PR status, menopause status, tumor progression and death of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    6. Sample ID, body site where sample was collected, analyte type of samples, tumor status, and histological type of samples obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
pht003008
Beschrijving

pht003008

De-identified sample ID
Beschrijving

SAMPID

Datatype

text

Alias
UMLS CUI [1,1]
C4684638
UMLS CUI [1,2]
C1299222
Body site where sample was collected
Beschrijving

BODY_SITE

Datatype

string

Alias
UMLS CUI [1,1]
C0449705
Analyte type
Beschrijving

ANALYTE_TYPE

Datatype

string

Alias
UMLS CUI [1,1]
C4744818
Cell or tissue type or subtype of sample
Beschrijving

HISTOLOGICAL_TYPE

Datatype

string

Alias
UMLS CUI [1,1]
C2713035
Tumor status
Beschrijving

IS_TUMOR

Datatype

string

Alias
UMLS CUI [1,1]
C0475752
Terug naar het begin van de pagina

Similar models

Sample ID, body site where sample was collected, analyte type of samples, tumor status, and histological type of samples obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.

6 Formulieren
  1. StudyEvent: SEV1
    1. Eligibility Criteria
    2. Subject ID, consent group, subject source, and subject source ID of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    3. Subject ID, family ID, father and mother IDs, and sex of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    4. Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    5. Subject ID, age, height, weight, tumor grade, tumor stage, histology of tumor, tumor ER, HER2, and PR status, menopause status, tumor progression and death of participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
    6. Sample ID, body site where sample was collected, analyte type of samples, tumor status, and histological type of samples obtained from participants with primary breast cancer and involved in the "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS-Trial)" project.
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
pht003008
SAMPID
Item
De-identified sample ID
text
C4684638 (UMLS CUI [1,1])
C1299222 (UMLS CUI [1,2])
BODY_SITE
Item
Body site where sample was collected
string
C0449705 (UMLS CUI [1,1])
ANALYTE_TYPE
Item
Analyte type
string
C4744818 (UMLS CUI [1,1])
HISTOLOGICAL_TYPE
Item
Cell or tissue type or subtype of sample
string
C2713035 (UMLS CUI [1,1])
IS_TUMOR
Item
Tumor status
string
C0475752 (UMLS CUI [1,1])
Terug naar het begin van de pagina